Stem cell companies moving to products
Crain’s Cleveland Business has an article reporting that investors and established companies are growing more interested in several adult stem-cell technologies. (Of course, given the current economic situation, investors are generally acting more shy than interested in anything.) The article discusses several companies focusing on those around Cleveland, Osiris is discussed, of course, but also Cytori, Athersys, Arteriocyte, AcelleRX Therapeutics. and Cell Targeting. (Our article In search of a business model also looks at this topic, primarily interviewing representatives of investors and big drug companies.)
Also relevant is a biotech start-up, Fate Therapeutics, which is using conventional drugs to target stem cells within patients’ own bodies. (See our article Stem cell therapies the old-fashioned way)
